Cantor Fitzgerald Reiterates Overweight Rating on CVRx Inc (CVRX)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $20.00 price target on CVRx Inc (NASDAQ: CVRX).

The analyst commented, “Following the market's close, OW-rated CVRx (CVRX) preannounced 1Q25 revenue of ~$12.3 million (Cantor $14.7 million / FactSet Consensus $14.7 million), representing YoY growth of ~15%. CVRX attributed the revenue miss to underperformance from newer sales representatives, as the company has been rebuilding its team and has had to perform with deeper cuts than initially anticipated, resulting in fewer seasoned reps. To a lesser extent, CVRX noted seasonal procedure softness tied to patient insurance dynamics that has become more evident this year relative to past years. CVRX increased active implanting centers by 4 QoQ, ending the quarter with 227 centers and exited 1Q25 with ~$102.7 million in cash. While we are disappointed by the soft start to the year and what will likely result in a negative revision to annual guidance, we believe investing in a stronger sales organization will result in a stronger company down the road. With shares down ~30% after market hours vs. SP565 down 0.6%, we believe the risk/reward favors the upside for those that can withstand nearterm volatility associated with the miss and macro environment.”

For an analyst ratings summary and ratings history on CVRx Inc click here. For more ratings news on CVRx Inc click here.

Shares of CVRx Inc closed at $11.54 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery